Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: The University of Alabama at Birmingham experience

Neuro-Oncology Practice

Volumn 1, Issue 4, 2014, Pages 172-177

  Clark, Grant M ^a   McDonald, Andrew M ^a   Nabors, Louis B ^a   Fathalla Shaykh, Hassan ^a   Han, Xiaosi ^a   Willey, Christopher D ^a   Markert, James M ^a   Guthrie, Barton L ^a   Bredel, Markus ^a   Fiveash, John B ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Bevacizumab; Glioblastoma; Hypofractionated radiation; Radiosurgery; Recurrent

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DYSARTHRIA; DYSPHASIA; FATIGUE; FEMALE; GLIOBLASTOMA; GROSS TUMOR VOLUME; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; MALE; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIOLOGICAL PARAMETERS; RETROSPECTIVE STUDY; SEIZURE; STEREOTACTIC RADIOSURGERY; TUMOR VOLUME; VERY ELDERLY; VISUAL DISORDER; WEAKNESS;

EID: 84974588648     PISSN: 20542577     EISSN: 20542585     Source Type: Journal    
DOI: 10.1093/nop/npu028     Document Type: Article

References (15)

1. Brandes AA. State-of-the-art treatment of high-grade brain tumors. Semin Oncol. 2003;30(6 suppl 19):4-9.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomintant and adjuvant temozolomide for glioblastoma. New Engl J Med. 2005;352(10):987-996.
3. Carson KA, Grossman SA, Fisher JD, et al. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol. 2007;25(18):3601-3606.
4. Lederman G, Wronski M, Arbit E, et al. Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol. 2000; 23(2):155-159.
5. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5): 4733-4740.
6. Vredenburgh JJ, Cloughesy T, Samant M, et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist. 2010;15(12): 1329-1334.
7. Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009; 75(1):156-163.
8. Cabrera AR, Cuneo KC, Desjardins A, et al. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. Int J Radiat Oncol Biol Phys. 2013;86(5):873-879.
9. Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiotherapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol. 2010;28(27):3048-3053.
10. Radiation Therapy Oncology Group Study 1205: Randomized phase II trial of concurrent bevacizumab with reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma. Clinicaltrials.gov identifier 1730950. http://clinicaltrials.gov/show/NCT01730950.
11. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11): 1963-1972.
12. Patel M, Siddiqui F, Jin JY, et al. Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neuroncol. 2009;92(2):185-191.
13. Torcuator RG, Thind R, Patel M, et al. The role of salvage reirradiation for malignant gliomas that progress on bevacizumab. J Neurooncol. 2010;97(3):401-407.
14. Niyazi M, Ganswindt U, Schwarz SB, et al. Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys. 2012;82(1):67-76.
15. Memorial Sloan-Kettering Cancer Institute. A phase I dose escalation study of hypofractionated stereotactic radiotherapy with bevacizumab in the treatment of recurrent malignant glioma. Clinicaltrials.gov identifier NCT 01392209. http://clinicaltrials.gov/show/NCT01730950.